Paul Morin PhD
About Paul Morin PhD
Paul Morin, PhD, is the Director and Research Fellow at Bristol Myers Squibb in Princeton, New Jersey, with extensive experience in gene therapy and protein engineering.
Company
Paul Morin PhD is currently employed at Bristol Myers Squibb, holding the position of Director and Research Fellow. He operates out of Princeton, New Jersey, United States. He oversees significant research projects and contributes actively to the organization's scientific advancements.
Title
As the Director and Research Fellow at Bristol Myers Squibb, Paul Morin PhD leads various research initiatives and directs key scientific projects. He is responsible for chairing the Discovery Working Group and plays a crucial role in the development of new biologics-based therapeutics.
Education and Expertise
Paul Morin PhD has a robust academic background in chemistry and biology, having earned a B.S. from Carnegie Mellon University from 1983 to 1987. He pursued a Ph.D. in Physical Biochemistry at The Johns Hopkins University from 1987 to 1991. His postdoctoral studies include research in Protein Biochemistry at the European Molecular Biology Laboratory (1991-1993) and NMR Spectroscopy at the Ontario Cancer Institute (1993-1996). His extensive education and research experience have endowed him with specialized knowledge in protein engineering, PK extension, protein stability, and gene therapy techniques.
Professional Background
Paul Morin's professional journey includes significant roles at several prestigious institutions. From 1992 to 1993, he worked as a Post Doctoral Fellow at the European Molecular Biology Laboratory and an Alexander von Humboldt Foundation Stipendiat in Heidelberg, Germany. He then served as a Post Doctoral Fellow at the Ontario Cancer Institute from 1994 to 1997 in Toronto, Canada. Between 1997 and 2004, he was the Principal Scientist at DuPont Merck Pharmaceuticals in Wilmington, Delaware. His cumulative experience has shaped his expertise in various biotech and pharmaceutical domains.
Research and Publications
Paul Morin PhD has a prolific research portfolio that includes extensive work in gene therapy, focusing on AAV programs and mRNA conjugates. He co-chaired a project that resulted in over 50 publications and obtained 12 patents. Notably, he has designed three first-author patents currently undergoing human studies. His expertise extends to developing cancer PET imaging tools and creating new biologics-based therapeutics aimed at treating various human diseases.